Home › Major Depressive Disorder › New York
Major Depressive Disorder clinical trials in New York
48 studies for Major Depressive Disorder are looking for participants at sites in New York.
Cities in New York
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Adams Clinical Bronx, The Bronx
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 1, 2026 · NCT07775300A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Integrative Clinical Trials LLC, Brooklyn
- SPRI Clinical Trials, LLC, Brooklyn
- Bioscience Research LLC, Mount Kisco
- and 3 more
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Oct 1, 2026 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Integrative Clinical Trials LLC, Brooklyn
- SPRI Clinical Trials, LLC, Brooklyn
- Bioscience Research LLC, Mount Kisco
- and 1 more
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT06559306A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Ima Clinical Research - Nyc Midtown, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07621237Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- SPRI Clinical Trials, LLC, Brooklyn
- Manhattan Behavioral Medicine, New York
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT05850689A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Adams Clinical Harlem, New York
- New York State Psychiatric Institute, New York
- Davis Clinical (Adams Clinical Bronx), The Bronx
- and 1 more
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, New York
- Vanda Investigational Site, New York
- Vanda Investigational Site, Staten Island
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044DBS for TRD With the Medtronic Percept PC
- Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York
Recruiting
Ages 25 to 70 · All sexes · Updated Sep 22, 2026 · NCT05773755Pattern Separation in Major Depressive Disorder
- New York State Psychiatric Institute (NYSPI), New York
RecruitingPhase 1
Ages 18 to 50 · All sexes · Updated Sep 15, 2026 · NCT07139834A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Brooklyn
- Seaport Investigator Site, Cedarhurst
- Seaport Investigator Site, New York
- and 1 more
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 14, 2026 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Integrative Clinical Trials LLC, Brooklyn
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 14, 2026 · NCT07284667A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Bioscience Research, LLC, Mount Kisco
- Fieve Clinical Research, Inc., New York
- IMA Clinical Research, New York
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 8, 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, New York
- Draig Clinical Site, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Mount Sinai Hospital, New York
Recruiting
Ages 22 to 70 · All sexes · Updated Aug 28, 2026 · NCT06423430A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 26, 2026 · NCT07300969NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Adams Clinical Harlem, New York
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 10, 2026 · NCT07592689NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cedarhurst
- Neurocrine Clinical Site, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06963021A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Adams Clinical Harlem, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 6, 2026 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Integrative Clinical Trials, Brooklyn
- Richmond Behavioral Associates, Staten Island
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 3, 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Neurobehavioral Research, Inc., Cedarhurst
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Aug 3, 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Neurobehavioral Research, Inc, Cedarhurst
- IMA Clinical Research - NYC Midtown, New York
- IMA Clinical Research - NYC Uptown, New York
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Glen Oaks
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07196501Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cedarhurst
- Neurocrine Clinical Site, Mount Kisco
- Neurocrine Clinical Site, New York
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Brooklyn
- Clinical Research Site, New York
- Clinical Research Site, New York
- and 2 more
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT07484217Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
- NYU Langone Health, New York
Recruiting
Ages 24 to 65 · All sexes · Updated Jun 29, 2026 · NCT07111390A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Ima Clinical Research - Manhattan /ID# 278212, New York
- Manhattan Behavioral Medicine /ID# 277910, New York
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997tDCS: Sleep to Mood in Depression (S2M-D)
- NYU Langone Health, New York
Recruiting
Ages 18 to 65 · All sexes · Updated Jun 8, 2026 · NCT07572526Triage Survey for Psychiatry Research Eligibility
- Adams Clinical, Harlem, New York
- Adams Clinical, Bronx, The Bronx
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT05800925A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- The Medical Research Network, LLC, New York
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830Aβ Dynamics in LLMD
- NYU Langone Health, New York
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg
RecruitingPhase 4
Ages 60 and older · All sexes · Updated May 6, 2026 · NCT05004987Mindfulness-Based fMRI Neurofeedback for Depression
- Columbia University Irving Medical Center, New York
Recruiting
Ages 13 to 18 · All sexes · Updated Apr 29, 2026 · NCT05617495Neutralizing Interleukin (IL)-6
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Apr 29, 2026 · NCT07493317Maintenance rTMS for Depression (Maitr-De)
- Weill Cornell Medicine, New York
Recruiting
Ages 18 to 80 · All sexes · Updated Apr 29, 2026 · NCT06938841Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality
- Weill Cornell Medicine, New York
Recruiting
Ages 50 to 80 · All sexes · Updated Mar 27, 2026 · NCT05925322Biomarker-guided rTMS for Treatment Resistant Depression
- Weill Cornell Medicine, New York
RecruitingPhase 3
Ages 22 to 65 · All sexes · Updated Feb 25, 2026 · NCT04041479The Role of mGluR5 in CBT-I
- Stony Brook University: Dept of Psychiatry, Stony Brook
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT07076342Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33
- NYU Langone Health, New York
- Nathan Kline Institute for Psychiatric Research, Orangeburg
Recruiting
Ages 18 to 65 · All sexes · Updated Feb 5, 2026 · NCT05573074Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #105, Brooklyn
- Autobahn Site #134, Brooklyn
- Autobahn Site #104, Staten Island
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jan 20, 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mount Kisco
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06786624From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.